$2.32T
Total marketcap
$107.82B
Total volume
BTC 49.94%     ETH 15.50%
Dominance

Repligen Corporation RGN.F Stock

163.5 EUR {{ price }} 0.708342% {{change_pct}}%
COUNTRY
Germany
Exchange
Frankfurt
Market Cap
9.13B EUR
LOW - HIGH [24H]
163.5 - 163.5 EUR
VOLUME [24H]
20 EUR
{{ volume }}
P/E Ratio
236.95
Earnings per share
0.69 EUR

Repligen Corporation Price Chart

Repligen Corporation RGN.F Financial and Trading Overview

Repligen Corporation stock price 163.5 EUR
Previous Close 147 EUR
Open 145.4 EUR
Bid 145.6 EUR x 19000
Ask 148.6 EUR x 19000
Day's Range 145.4 - 145.4 EUR
52 Week Range 130 - 250 EUR
Volume 23 EUR
Avg. Volume 3 EUR
Market Cap 8.1B EUR
Beta (5Y Monthly) 1.064788
PE Ratio (TTM) 53.45588
EPS (TTM) 0.69 EUR
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 282.5 EUR

RGN.F Valuation Measures

Enterprise Value 8.18B EUR
Trailing P/E 53.45588
Forward P/E 48.145695
PEG Ratio (5 yr expected) 2.94
Price/Sales (ttm) 10.408734
Price/Book (mrq) 4.1694145
Enterprise Value/Revenue 10.513
Enterprise Value/EBITDA 35.872

Trading Information

Repligen Corporation Stock Price History

Beta (5Y Monthly) 1.064788
52-Week Change 13.16%
S&P500 52-Week Change 20.43%
52 Week High 250 EUR
52 Week Low 130 EUR
50-Day Moving Average 148.42 EUR
200-Day Moving Average 171.27 EUR

RGN.F Share Statistics

Avg. Volume (3 month) 3 EUR
Avg. Daily Volume (10-Days) 2 EUR
Shares Outstanding 55.68M
Float 51.89M
Short Ratio N/A
% Held by Insiders 6.76%
% Held by Institutions 97.79%
Shares Short N/A
Short % of Float N/A
Short % of Shares Outstanding N/A

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2022
Most Recent Quarter (mrq) March 31, 2023
Next Fiscal Year End December 31, 2023

Profitability

Profit Margin 21.57%
Operating Margin (ttm) 22.31%
Gross Margin 55.60%
EBITDA Margin 29.30%

Management Effectiveness

Return on Assets (ttm) 4.40%
Return on Equity (ttm) 9.05%

Income Statement

Revenue (ttm) 777.8M EUR
Revenue Per Share (ttm) 14.01 EUR
Quarterly Revenue Growth (yoy) -11.50%
Gross Profit (ttm) 455.71M EUR
EBITDA 227.95M EUR
Net Income Avi to Common (ttm) 167.82M EUR
Diluted EPS (ttm) 2.72
Quarterly Earnings Growth (yoy) -38.60%

Balance Sheet

Total Cash (mrq) 618.02M EUR
Total Cash Per Share (mrq) 11.1 EUR
Total Debt (mrq) 420.7M EUR
Total Debt/Equity (mrq) 21.68 EUR
Current Ratio (mrq) 2.514
Book Value Per Share (mrq) 34.873

Cash Flow Statement

Operating Cash Flow (ttm) 160.12M EUR
Levered Free Cash Flow (ttm) 15.41M EUR

Profile of Repligen Corporation

Country Germany
State MA
City Waltham
Address Building 1
ZIP 02453
Phone 781 250 0111
Website https://www.repligen.com
Industry Medical Instruments & Supplies
Sector(s) Healthcare
Full Time Employees 2025

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Q&A For Repligen Corporation Stock

What is a current RGN.F stock price?

Repligen Corporation RGN.F stock price today per share is 163.5 EUR.

How to purchase Repligen Corporation stock?

You can buy RGN.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Repligen Corporation?

The stock symbol or ticker of Repligen Corporation is RGN.F.

Which industry does the Repligen Corporation company belong to?

The Repligen Corporation industry is Medical Instruments & Supplies.

How many shares does Repligen Corporation have in circulation?

The max supply of Repligen Corporation shares is 55.84M.

What is Repligen Corporation Price to Earnings Ratio (PE Ratio)?

Repligen Corporation PE Ratio is 236.95653000 now.

What was Repligen Corporation earnings per share over the trailing 12 months (TTM)?

Repligen Corporation EPS is 0.69 EUR over the trailing 12 months.

Which sector does the Repligen Corporation company belong to?

The Repligen Corporation sector is Healthcare.